Ubs Asset Management Americas Inc Anavex Life Sciences Corp. Transaction History

Ubs Asset Management Americas Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$8.32 - $11.75 $806,407 - $1.14 Million	96,924 New	96,924 $830,000
Q2 2022 Aug 12, 2022	BUY	$7.31 - $12.84 $232,889 - $409,069	31,859 Added 49.48%	96,244 $963,000
Q4 2021 Feb 14, 2022	SELL	$16.88 - $23.31 $73,698 - $101,771	-4,366 Reduced 6.35%	64,385 $1.12 Million
Q3 2021 Nov 15, 2021	BUY	$16.82 - $25.75 $9,536 - $14,600	567 Added 0.83%	68,751 $1.23 Million
Q2 2021 Aug 16, 2021	BUY	$10.16 - $28.86 $692,749 - $1.97 Million	68,184 New	68,184 $1.56 Million

163

27.5M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $673M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.